Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.30 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18594394 | 1.00 | GRM2 (0.43) | GRM2EPHX1GRM3GAAGABRR1 | |
| SCHEMBL13823191 | 1.00 | GRM2 (0.43) | GRM2EPHX1GRM3GAAGABRR1 | |
| SCHEMBL18594378 | 1.00 | GRM2 (0.43) | GRM2EPHX1GRM3GAAGABRR1 | |
| SCHEMBL18594393 | 1.00 | GRM2 (0.43) | GRM2EPHX1GRM3GAAGABRR1 | |
| SCHEMBL21082226 | 1.00 | GRM2 (0.43) | GRM2EPHX1GRM3GAAGABRR1 | |
| SCHEMBL13924805 | 0.83 | EPHX1 (0.41) | GRM2EPHX1GRM3GAA | |
| SCHEMBL2515401 | 0.83 | GRM2 (0.42) | GRM2EPHX1GRM3GAA | |
| SCHEMBL18717710 | 0.83 | EPHX1 (0.41) | GRM2EPHX1GRM3GAA | |
| SCHEMBL29567942 | 0.78 | GRM2 (0.38) | GRM2EPHX1GRM3GAA | |
| SCHEMBL12780746 | 0.77 | GRM2 (0.40) | GRM2GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170174713-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174713-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | GRM2 2918/4885EPHX1 4038/4885GRM3 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.